These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 30354612)

  • 1. Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
    Sarrias A; Bayes-Genis A
    Circulation; 2018 Aug; 138(6):551-553. PubMed ID: 30354612
    [No Abstract]   [Full Text] [Related]  

  • 2. The potential antiarrhythmic properties of sacubitril/valsartan: a case report.
    Castiello A; Sciatti E; Gavazzoni M; Vizzardi E; Metra M
    J Cardiovasc Med (Hagerstown); 2019 Nov; 20(11):780-782. PubMed ID: 31580305
    [No Abstract]   [Full Text] [Related]  

  • 3. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?
    Del Buono MG; Bonaventura A; Vecchié A; Wohlford GF; Dixon DL; Van Tassel BW; Abbate A
    J Cardiovasc Pharmacol; 2020 Feb; 75(2):105-107. PubMed ID: 31815825
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of sacubitril / valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Failure Sections of the Polish Cardiac Society.
    Grabowski M; Ozierański K; Balsam P; Dąbrowski R; Farkowski MM; Gackowski A; Jędrzejczyk-Patej E; Kalarus Z; Leszek P; Nessler J; Sterliński M; Opolski G; Przybylski A
    Kardiol Pol; 2019 Oct; 77(10):987-993. PubMed ID: 31527563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What will be the impact of sacubitril/valsartan in clinical practice?
    Metra M
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e88-e90. PubMed ID: 29084021
    [No Abstract]   [Full Text] [Related]  

  • 7. Sacubitril/valsartan: An antiarrhythmic drug?
    Huang E; Bernard ML; Elise Hiltbold A; Khatib S; Polin GM; Rogers PA; Dominic P; Morin DP
    J Cardiovasc Electrophysiol; 2022 Nov; 33(11):2375-2381. PubMed ID: 36069136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the glass half full or half empty after PARAGON-HF?
    Cohen-Solal A; Logeart D
    Cardiovasc Res; 2020 Jan; 116(1):e5-e7. PubMed ID: 31850504
    [No Abstract]   [Full Text] [Related]  

  • 9. Sacubitril/valsartan (Entresto) for heart failure.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):107-9. PubMed ID: 26218791
    [No Abstract]   [Full Text] [Related]  

  • 10. Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
    Januzzi JL; Camacho A; Piña IL; Rocha R; Williamson KM; Maisel AS; Felker GM; Prescott MF; Butler J; Solomon SD;
    Circ Heart Fail; 2020 Jun; 13(6):e006946. PubMed ID: 32482089
    [No Abstract]   [Full Text] [Related]  

  • 11. Sacubitril/valsartan, ivabradine hydrochloride, alirocumab, and evolocumab.
    Hussar DA; Abdelsayed M
    J Am Pharm Assoc (2003); 2015; 55(6):674-678. PubMed ID: 26547602
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
    Ahn R; Prasad V
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):633-635. PubMed ID: 30232657
    [No Abstract]   [Full Text] [Related]  

  • 14. In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?
    Bonaventura A; Wohlford GF; Vecchié A; Van Tassel BW; Abbate A
    J Cardiovasc Pharmacol; 2019 Jul; 74(1):1-3. PubMed ID: 31274835
    [No Abstract]   [Full Text] [Related]  

  • 15. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
    Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case of Palpitations Due to T-Wave Oversensing Caused by Sacubitril/Valsartan.
    Chiu MH; Howlett JG; Kuriachan VP; Sharma NC
    Can J Cardiol; 2018 Aug; 34(8):1089.e1-1089.e3. PubMed ID: 29960804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
    Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/valsartan: from a large clinical trial to clinical practice.
    Sciatti E; Senni M; Lombardi CM; Gori M; Metra M
    J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):473-479. PubMed ID: 29917003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
    Haynes R; Judge PK; Staplin N; Herrington WG; Storey BC; Bethel A; Bowman L; Brunskill N; Cockwell P; Hill M; Kalra PA; McMurray JJV; Taal M; Wheeler DC; Landray MJ; Baigent C
    Circulation; 2018 Oct; 138(15):1505-1514. PubMed ID: 30002098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.